Short answer
Edgewise Therapeutics, Inc. (EWTX) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Servier completed acquisition of sevasemten and Edgewise’s muscular dystrophy program on July 10, 2026.
Edgewise Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Servier completed acquisition of sevasemten and Edgewise’s muscular dystrophy program on July 10, 2026
- Edgewise received $1.55 billion in upfront cash consideration
- Additional milestone payments could reach $1.1 billion
- Total potential transaction value up to $2.65 billion
- Asset sale materially monetizes the muscular dystrophy program while shifting future value realization to milestones
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclosure language only
- No substantive company event or investor-actionable information disclosed
- No financial, operational, or strategic updates provided
Item EX-99.1 · Exhibit EX-99.1
- Servier transaction closed for $1.55B upfront cash plus up to $1.1B milestones, materially strengthening Edgewise’s balance sheet
- Edgewise exits muscular dystrophy and becomes cardiovascular-focused, retaining EDG-7500, EDG-15400 and EDG-003
- Upfront proceeds plus existing cash expected to fund EDG-7500 through potential approval, reducing near-term financing risk
- EDG-7500 Phase 3 trial expected in Q4 2026 following positive 12-week Phase 2 data
- Sevasemten Becker pivotal cohort fully enrolled with 175 participants; top-line data expected Q4 2026, while future milestones remain contingent on execution and approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edgewise Therapeutics, Inc. 8-K filings
Get the next EWTX 8-K as it lands
Follow EWTX for push alerts, or ask the research agent what this filing means.